Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03256526 · ClinicalTrials.gov registry record · Phase 2
6-week Safety and PD Study in Adults With NAFLD
A Phase 2 study of Non-alcoholic Fatty Liver Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 9
- Study locations
NCT03256526 is a Phase 2 study of Non-alcoholic Fatty Liver Disease that has completed, run by Pfizer. The registered enrollment target is 53 participants, below the 189-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (72% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT03256526, a Phase 2 study of Non-alcoholic Fatty Liver Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 9
- Study locations
Study Summary
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-06835919 Low Dose
- DRUG PF-06835919 High Dose
Study Locations (9)
Florida
- Avail Clinical Research, LLC - DeLand
- Stand-Up MRI of Miami - Miami
- Avail Clinical Research, LLC - Orange City
- Qps-Mra, Llc - South Miami
California
- National Research Institute - Los Angeles
Ohio
- Sterling Research Group, Ltd. - Cincinnati
Tennessee
- WR-ClinSearch LLC - Chattanooga
Texas
- Clinical Trials of Texas, Inc. - San Antonio
Virginia
- National Clinical Research, Inc - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2018-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03256526
The ClinicalTrials.gov registry entry for NCT03256526 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 50 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (72% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03256526 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT03256526 about?
NCT03256526 is a clinical study titled "6-week Safety and PD Study in Adults With NAFLD". IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
What is the current status of trial NCT03256526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2017-09-27. Estimated completion is 2018-04-27.
What conditions does trial NCT03256526 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT03256526?
The interventions under investigation include: Placebo (DRUG), PF-06835919 Low Dose (DRUG), PF-06835919 High Dose (DRUG).
Who is sponsoring clinical trial NCT03256526?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03256526 being conducted?
This trial has 9 study locations across California, Florida, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
RECRUITING · Phase 2
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2b Study of GSK4532990 in Adults With NASH
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.